Irradiation of the whole breast after surgery is the standard of care in many patients with breast cancer or pre-invasive lesions. The inclusion of IMNs in the irradiation field gained attention many years ago to control common occult lymph node metastases. Nonetheless, initial results were unsatisfactory and non-cancer-related mortality and morbidity mainly owing to cardiac and lung complications were a valid concern (
18-
20). Advances in radiotherapy delivery methods, however, resulted in enhanced treatment outcomes. In 2012, after an average follow-up of 6.2 years, Olson et al. reported that IMN radiation was not associated with significantly improved survival in all patients; however, they suggested that its application in individuals with low-burden lymph node involvement (N1) could improve patients’ outcome (
21). Later in 2015, a study on approximately 4 000 patients with early-stage breast cancer showed significantly improved disease-free survival, less distant metastasis, and marginal improvement in overall survival. Moreover, while a significantly reduced breast cancer-related mortality was achieved, no treatment-related mortality occurred (
6). In the same year, the results of another large study known as the MA.20 trial was published, which indicated that compared to whole breast irradiation alone, patients treated with comprehensive regional irradiation plus whole-breast irradiation had a reduced risk of breast cancer recurrence, both in the regional nodes and at distant sites (
5).
A persistent dilemma exists regarding the best radiotherapy technique that provides IMN coverage while contributing to fewer adverse events. In the present study, we found a higher mean dose delivered to the IMN by the P/E technique compared to the PWT method. This was in contrast with the results published by Severin et al., but consistent with the findings of a more recent study by Dumane et al. in 2014 (
17,
22). In the latter study, the V95% for the target, which included the chest wall and the nodes, was > 95% for both the PWT and photon/electron techniques (
22). Nonetheless, the highest V95% observed in our study was 94.5% in BCS patients treated with the P/E plan.
In line with previous studies, we found that the formation of hotspots was significantly more prevalent among patients treated with the P/E mix plan (
17,
23). When comparing results across mastectomy and lumpectomy patients, our study demonstrated that the P/E technique retained many of its advantages of target coverage and toxicity regardless of the type of surgery. This finding was similar to the results of the study by Severin et al. The authors of the mentioned study, however, reported a significant difference regarding the mean dose of the IMN in patients treated with the PWT plan based on their primary surgical procedure (
17). We did not observe such a difference in our study.
Previous studies have been inconclusive regarding the superiority of a specific technique in causing less radiation-induced toxicity. Some studies have shown that the PWT technique leads to an increased depth of normal tissue exposed to radiation and, thus, have proposed that using a combination of photons and electrons could significantly decrease the amount of lung and heart exposure to high-dose radiation (
17,
22,
24). On the other side, several studies indicated that cardiac substructures receive more radiation exposure after radiotherapy with a P/E beam and the least exposure with PWT (
23,
25). In the present study, we found a significantly higher volume of the heart and lungs to be irradiated with the PWT plan compared to the P/E technique. Also, in both techniques, the extent of heart and lung exposure within BCS patients was greater than in MRM patients, which was in contrast to the results of a previous study (
17).
Previous studies have shown that significant radiological and symptomatic radiation pneumonitis does not usually occur unless the V20Gy of the lung is above 30% (
26,
27). In the present study, only MRM patients irradiated with the PWT technique reached this threshold. As for cardiac toxicity, long-term follow-up of patients in randomized clinical trials revealed that radiation exposure of the heart during breast cancer radiotherapy increases the subsequent risk of heart disease (
28). Marks et al. proposed that radiation therapy causes volume-dependent cardiac perfusion defects in approximately 40% of patients within 2 years of RT. They showed an incidence of < 20% for fields involving < 5% of the LV versus > 50% when > 5% of the LV was irradiated (
29). In another study, Wei et al. reported the V30 of the heart as a predictor for pericardial effusion with the risk of effusion being 13% and 73% if V30 was below or above 46%, respectively (
30). In this study, the largest mean volume of the heart irradiated was 13.6% with the PWT and 9.2% with the P/E technique, meaning a low risk of effusion for both techniques, but a relatively high possibility of perfusion defects. As such, reducing post-radiation heart damage remains an important goal to be achieved.
Another organ that is at risk of unintended radiation and, thus, requires protection is the contralateral breast. A recent study investigating internal mammary nodal radiation for breast cancer showed an increase in the overall survival of patients; however, this came at the cost of a higher incidence of contralateral breast cancer in the survivors (
31). Severin et al. showed that the volume of the contralateral breast receiving 2.5 Gy (5% of the prescribed dose) was 24.5% with PWT and 4% with P/E (
17). This was in contrast with the results of our study, which indicated a noticeably greater volume of the right breast being irradiated with the P/E plan compared to the PWT technique. Dumane et al. reported differences in doses to the contralateral breast to be insignificant amongst all 3D techniques (
22).
A study conducted in 2003 by Fiets et al. showed that including regional lymph nodes in the target volume (with a dose of 2 Gy per fraction) is associated with a significantly higher risk of esophagitis or dysphagia as 53% of patients treated with locoregional radiotherapy concurrent with chemotherapy developed high-grade esophagitis or dysphagia, compared to only 12% of patients treated with local radiotherapy. They concluded that the type of primary surgical treatment was not significantly associated with any of these complications (
32). This finding was consistent with the results of our study, indicating no significant difference in the maximum dose delivered to the esophagus based on patients’ type of surgery. In addition, several previous studies have indicated an increased risk of esophageal carcinoma among patients undergoing radiotherapy for breast cancer. However, due to a lack of information, the dose level, which would contribute to esophageal carcinoma, was not specified (
33,
34).
As with any other study, this study was also associated with some limitations. For example, in this study, we did not investigate the effect of variables such as the depth of the ipsilateral lung, chest wall separation, and length of the lung on our outcomes. Also, the patient’s characteristics such as body size, weight, breast size, and also the stage of disease were not included in our analysis. Moreover, the outcomes of only two radiotherapy techniques were compared. Thus, we suggest a larger trial that provides dosimetric data of further advanced techniques and conducts subgroup analysis to measure the effect of the mentioned variables.
5.1. Conclusions
In summary, the P/E mix plan provided a higher target coverage of the left breast and the IMNs plus more sparing of the heart and lungs. However, these benefits came at the cost of a higher dose to the esophagus and greater contralateral breast irradiated volume compared to the PWT technique. Considering this, we recommend that when designing treatment plans, clinicians take into account on an individual basis the competing risks of each technique and whether or not to include regional lymph nodes.